title: Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin.
abstract: The aim of this study was to evaluate the medium term effects of the selective alpha1-adrenenergic- blocker terazocin on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally for 30 days. The daily dose was 1 mg for the first 7 days, 2 mg for the next 7 days and 5 mg for the remaining period of this clinical trial. At the end of this clinical trial, plasma ANP levels increased by 16.40% despite the drop in blood pressure while left atrial and ventricular diameters remained unchanged. These findings indicate that the increase of ANP plasma levels is not the result of a mechanical load on the left cardiac chambers but the result of a pharmacological action. These observations also indicate that terazocin exerts part of its antihypertensive action by increasing ANP plasma levels.
authors.affiliation: Department of 2nd Cardiology, Medical School, Aristotle University of Thesssaloniki, Greece.
authors.forename: P
authors.initials: P
authors.lastname: Kotridis
authors.forename: B
authors.initials: B
authors.lastname: Kokkas
authors.forename: P
authors.initials: P
authors.lastname: Kyriakou
authors.forename: M
authors.initials: M
authors.lastname: Karamouzis
authors.forename: G
authors.initials: G
authors.lastname: Salpigidis
authors.forename: C
authors.initials: C
authors.lastname: Karantona
authors.forename: J
authors.initials: J
authors.lastname: Karadoumanis
authors.forename: T
authors.initials: T
authors.lastname: Ginis
authors.forename: O
authors.initials: O
authors.lastname: Goulis
authors.forename: P C
authors.initials: PC
authors.lastname: Papadopoulos
authors.forename: C
authors.initials: C
authors.lastname: Vakalopoulos
authors.forename: G
authors.initials: G
authors.lastname: Sakantamis
authors.forename: A
authors.initials: A
authors.lastname: Dimitriadou
authors.forename: V
authors.initials: V
authors.lastname: Mirtsou-Fidani
authors.forename: C L
authors.initials: CL
authors.lastname: Papadopoulos
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D009320:Atrial Natriuretic Factor / Q000097:blood*; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D009320:Atrial Natriuretic Factor; C041226:Terazosin; D011224:Prazosin